ES2571741T3 - Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa - Google Patents
Bencimidazoles sustituidos como inhibidores de Mps-1 quinasaInfo
- Publication number
- ES2571741T3 ES2571741T3 ES12710760T ES12710760T ES2571741T3 ES 2571741 T3 ES2571741 T3 ES 2571741T3 ES 12710760 T ES12710760 T ES 12710760T ES 12710760 T ES12710760 T ES 12710760T ES 2571741 T3 ES2571741 T3 ES 2571741T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula general (I) : **Fórmula** en la que: A representa **Fórmula** en las que * indica el punto de unión de dichos grupos con el resto de la molécula; Z representa un grupo -C(>=O)N(H)R1 o -C(>=S)N(H)R1; R1 representa un átomo de hidrógeno o un grupo alquil C1-C6- o cicloalquil C3-C6-; en el que dicho grupo alquil C1-C6- o cicloalquil C3-C6- está opcionalmente sustituido, de forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, -OH, -CN, alquil C1-C6-, alcoxi C1-C6-; R2 representa un átomo de hidrógeno o un grupo alquil C1-C6- o cicloalquil C3-C6-; en el que dicho grupo alquil C1-C6- o cicloalquil C3-C6- está opcionalmente sustituido, de forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, OH, -CN, alquil C1-C6-, alcoxi C1-C6-; R3 representa un átomo de hidrógeno o un átomo de halógeno o un grupo -CN, alquil C1-C6-, -(CH2)m-alquenilo C2-C6, -(CH2)mcicloalquenilo C4-C8, -(CH2)m-alquinilo C2-C6, -(CH2)m-cicloalquilo C3-C6, -(CH2)m-(heterocicloalquilo de 3 a 7 miembros), -(CH2)m-(heterocicloalquenilo de 4 a 8 miembros), -aril-alquil C1-C6-, heteroaril-alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)N-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-, cicloalquil C3-C6-, heterocicloalquil de 3 a 7 miembros-, alquenil C2-C6-, cicloalquenil C4-C8-, alquinil C2-C6-, aril-, -alquil C1-C6-arilo, -alquil C1-C6-heteroarilo, heteroaril-, alquil C1-C6-X-, -X-(CH2)m-alquenilo C2-C6, -X-(CH2)mcicloalquenilo C4-C8, -X-(CH2)m-alquinilo C2-C6, -X-(CH2)m-cicloalquilo C3-C6, -X-(CH2)m-(heterocicloalquilo de 3 a 7 miembros), -X-(CH2)m-(heterocicloalquenilo de 4 a 8 miembros), aril-X-, heteroaril-X-, -C(>=O)R6, -C(>=O)N(H)R6a, -C(>=O)N(R6a)R6b, -C(>=O)O-R6, -N(R6a)R6b, -NO2, -N(H)C(>=O)R6, -OR6, -SR6, -S(>=O)R6, -S(>=O)2R6, -S(>=O)(>=NR6a)R6b, -S(>=O)2N(R6b)R6c, -S-(CH2)n-N(R6a)R6b, o -S-(CH2)n-(heterocicloalquilo de 3 a 7 miembros); estando dicho alquil C1-C6-, -(CH2)m-alquenilo C2-C6, -(CH2)m-alquinilo C2-C6, -(CH2)m-cicloalquilo C3-C6, aril-alquil C1-C6-, heteroaril-alquil C1-C6-, cicloalquil C3-C6-, heterocicloalquil de 3 a 7 miembros-, alquenil C2-C6-, cicloalquenil C4-C8-, alquinil C2-C6-, aril-, alquil C1-C6-X-, -X-(CH2)m-alquenilo C2-C6, -X-(CH2)mcicloalquenilo C4-C8, -X-(CH2)m-alquinilo C2-C6, -X-(CH2)m-cicloalquilo C3-C6, -X-(CH2)m-(heterocicloalquilo de 3 a 7 miembros), -X-(CH2)m-(heterocicloalquenilo de 4 a 8 miembros), aril-X-, heteroaril-X-, -alquil C1-C6-arilo, -alquil C1-C6-heteroarilo o heteroaril- que está opcionalmente sustituido, de forma idéntica o diferente, con 1, 2, 3, 4 o 5 grupos R7; 30 R4a, R4b, R4c, R4d, representan, independientemente entre sí, un átomo de hidrógeno o halógeno, o un grupo -CN, alquil C1-C6-, alcoxi C1-C6-, halo-alquil C1-C6-, halo-alcoxi C1-C6-, R6a(R6b)N-alquil C1-C6-, HO-alquil C1-C6-, NC-alquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-; R5 representa un átomo de hidrógeno o un grupo alquil C1-C6-, -(CH2)n-alquenilo C2-C6, -(CH2)n-alquinilo C2-C6, - (CH2)m-cicloalquilo C3-C6, -(CH2)m-(heterocicloalquilo de 3 a 7 miembros), aril-alquil C1-C6-, heteroaril-alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)N-alquil C1-C6-, HO-alquil C1-C6-, -alquil C1-C6-CN, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-, cicloalquil C3-C6-, heterocicloalquil de 3 a 7 miembros-, cicloalquenil C4-C8-, aril- o heteroaril-; estando dicho grupo alquil C1-C6-, -(CH2)n-alquenilo C2-C6, -(CH2)n-alquinilo C2-C6, -(CH2)m-cicloalquilo C3-C6, -(CH2)m-(heterocicloalquilo de 3 a 7 miembros), aril-alquil C1-C6-, heteroaril-alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)N-alquil C1-C6-, HO-alquil C1-C6-, -alquil C1-C6-CN, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-, cicloalquil C3-C6-, heterocicloalquil de 3 a 7 miembros-, cicloalquenil C4-C8-, aril- o heteroaril- opcionalmente sustituido, de forma idéntica o diferente, con 1, 2, 3, 4 o 5 grupos R8; R6, R6a, R6b, R6c representan, independientemente de si, un átomo de hidrógeno o un grupo alquil C1-C6-, HO-alquil C1-C6-, cicloalquil C3-C6-, alquenil C2-C6-, heterocicloalquil de 3 a 7 miembros-, aril-, heteroaril-, aril-alquil C1-C6- o heteroaril-alquil C1-C6-; R7 representa un átomo de hidrógeno o halógeno o un grupo HO-, -CN, alcoxi C1-C6-, halo-alcoxi C1-C6-, alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)N-alquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, heterocicloalquil de 3 a 7 miembros-, aril-, heteroaril-, -C(>=O)R6, -15 C(>=O)N(H)R6a, -C(>=O)N(R6a)R6b, -C(>=O)O-R6, -N(R6a)R6b, -NO2, -N(H)C(>=O)R6, -N(R6c)C(>=O)R6, -N(H)C(>=O)N(Rba)R6b, -N(R6c)C(>=O)N(R6a)R6b, -N(H)C(>=O)OR6, -N(R6c)C(>=O)OR6, -N(H)S(>=O)R6, -N(R6c)S(>=O)R6 -N(H)S(>=O)2R6, -N(R6c)S(>=O)2R6, -N>=S(>=O)(R6a)R6b, -OR6, -O(C>=O)R6, -O(C>=O)N(R6a)R6b, -O(C>=O)OR6, -SR6, -SF5, -S(>=O)R6, -S(>=O)N(H)R6, -S(>=O)N(R6a)R6b, -S(>=O)2R6, -S(>=O)2N(H)R6, -S(>=O)2N(R6a)R6b o -S(>=O)(>=NR6c)R6; en el que dicho grupo aril- o heteroaril- está opcionalmente sustituido, de forma idéntica o diferente, con 1, 2 o 3 grupos alquil C1-C6-; o cuando 2 grupos R7 están presentes en posición orto entre sí en un anillo de arilo, dichos 2 grupos R7 en conjunto forman un puente: *O(CH2)2O*, *O(CH2)O*, *NH(C(>=O))NH*, en los que * representa el punto de unión a dicho anillo de arilo; R8 representa un átomo de hidrógeno o halógeno o un grupo -CN, alcoxi C1-C6-, alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)N-alquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, heterocicloalquil de 3 a 7 miembros-, aril-, heteroaril-, -C(>=O)R6, -C(>=O)N(H)R6a, -C(>=O)N(R6a)R6b, -C(>=O)O-R6, -N(R6a)R6b, -NO2, -N(H)C(>=O)R6, -N(R6c)C(>=O)R6, -N(H)C(>=O)N(R6a)R6b, -N(R6c)C(>=O)N(R6a)R6b, -N(H)C(>=O)OR6, -N(R6c)C(>=O)OR6, -N(H)S(>=O)R6, -N(R6c)S(>=O)R6, -N(H)S(>=O)2R6, -N(R6c)S(>=O)2R6, -N>=S(>=O)(R6a)R6b, -OR6, -O(C>=O)R6, -O(C>=O)N(R6a)R6b, -O(C>=O)OR6, -SR6, -S(>=O)R6, -S(>=O)N(H)R6, -S(>=O)N(R6a)R6b, -S(>=O)2R6, -S(>=O)2N(H)R6, -S(>=O)2N(R6a)R6b, -S(>=O)(>=NR6c)R6 o -S(>=O)2-(heterocicloalquilo de 3 a 7 miembros); en el que dicho grupo heterocicloalquil de 3 a 7 miembros- o heteroaril-, está opcionalmente sustituido, de forma idéntica o diferente, con 1, 2, 3 o 4 grupos alquil C1-C6-; m es un número entero de 0, 1, 2, 3, 4, 5, o 6; n es un número entero de 0, 1, 2, 3, 4, o 5; y X es S, S(>=O), S(>=O)2, O, NR6, CR6aR6b, C(>=CR6aR6b), C(>=O) o C(OH)(R6a) ; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato, o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11160696 | 2011-03-31 | ||
EP11170306 | 2011-06-17 | ||
EP11190249 | 2011-11-23 | ||
PCT/EP2012/055562 WO2012130905A1 (en) | 2011-03-31 | 2012-03-28 | Substituted benzimidazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2571741T3 true ES2571741T3 (es) | 2016-05-26 |
Family
ID=45888240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12710760T Active ES2571741T3 (es) | 2011-03-31 | 2012-03-28 | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa |
Country Status (7)
Country | Link |
---|---|
US (1) | US9388140B2 (es) |
EP (1) | EP2691375B1 (es) |
JP (1) | JP6001049B2 (es) |
CN (1) | CN103582632B (es) |
CA (1) | CA2831710A1 (es) |
ES (1) | ES2571741T3 (es) |
WO (1) | WO2012130905A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2996876B1 (fr) | 2012-10-17 | 2015-02-06 | Peugeot Citroen Automobiles Sa | Moteur hybride pneumatique-thermique |
FR2996820B1 (fr) | 2012-10-17 | 2014-11-14 | Peugeot Citroen Automobiles Sa | Structure de caisse d'un vehicule automobile |
PL3283642T3 (pl) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B.V. | Biomarkery prognostyczne dla chemioterapii inhibitorem TTK |
WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
CA3081553C (en) | 2017-11-17 | 2022-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
JP7358657B2 (ja) * | 2020-10-28 | 2023-10-10 | 塩野義製薬株式会社 | 抗ウイルス活性を有するアミド誘導体 |
JP7454729B2 (ja) | 2022-04-27 | 2024-03-22 | 塩野義製薬株式会社 | 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
IL113472A0 (en) | 1994-04-29 | 1995-07-31 | Lilly Co Eli | Non-peptidyl tachykinin receptor antogonists |
WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
WO1997025041A1 (en) | 1996-01-09 | 1997-07-17 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
WO1997031635A1 (en) | 1996-03-01 | 1997-09-04 | Eli Lilly And Company | Methods of treating or preventing sleep apnea |
CA2248013A1 (en) | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Methods of treating or preventing interstitial cystitis |
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US20020072530A1 (en) | 2000-02-01 | 2002-06-13 | Bing-Yan Zhu | Indole and benzimidazole inhibitors of factor Xa |
EP1379520B2 (en) * | 2001-02-23 | 2014-04-09 | Merck Sharp & Dohme Corp. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
JP2009530409A (ja) | 2006-03-23 | 2009-08-27 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物 |
KR20100023907A (ko) | 2007-06-26 | 2010-03-04 | 사노피-아벤티스 | 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성 |
CN101903026B (zh) | 2007-09-18 | 2013-05-08 | 斯坦福大学 | 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途 |
US8729082B2 (en) | 2009-04-29 | 2014-05-20 | Bayer Intellectual Property Gmbh | Substituted imidazoquinoxalines |
TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
CN102596932A (zh) | 2009-09-04 | 2012-07-18 | 拜耳医药股份有限公司 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
-
2012
- 2012-03-28 CA CA2831710A patent/CA2831710A1/en not_active Abandoned
- 2012-03-28 WO PCT/EP2012/055562 patent/WO2012130905A1/en active Application Filing
- 2012-03-28 ES ES12710760T patent/ES2571741T3/es active Active
- 2012-03-28 US US14/008,981 patent/US9388140B2/en not_active Expired - Fee Related
- 2012-03-28 EP EP12710760.5A patent/EP2691375B1/en not_active Not-in-force
- 2012-03-28 JP JP2014501605A patent/JP6001049B2/ja not_active Expired - Fee Related
- 2012-03-28 CN CN201280026372.0A patent/CN103582632B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP6001049B2 (ja) | 2016-10-05 |
US9388140B2 (en) | 2016-07-12 |
WO2012130905A1 (en) | 2012-10-04 |
CN103582632A (zh) | 2014-02-12 |
EP2691375A1 (en) | 2014-02-05 |
CN103582632B (zh) | 2015-08-19 |
US20140302010A1 (en) | 2014-10-09 |
EP2691375B1 (en) | 2016-03-16 |
CA2831710A1 (en) | 2012-10-04 |
JP2014509625A (ja) | 2014-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2571741T3 (es) | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa | |
AR082946A1 (es) | Imidazopiridazinas sustituidas | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR099823A1 (es) | Compuestos bicíclicos de 7 eslabones | |
AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
EA201171062A1 (ru) | Алкиламидные соединения и их применение | |
UA117151C2 (uk) | N-ациліміногетероциклічні сполуки | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR095570A1 (es) | Derivados de urea | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
CO6801734A2 (es) | Derivados de etinilo como moduladores alostéricos positivos de mglur5 | |
ES2530802T3 (es) | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos | |
AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek |